Nautilus Biotechnology (NASDAQ:NAUT) Issues Quarterly Earnings Results

Nautilus Biotechnology (NASDAQ:NAUT) issued its earnings results on Tuesday. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02, Yahoo Finance reports. During the same period last year, the company posted ($0.13) earnings per share.

Nautilus Biotechnology Price Performance

Shares of NASDAQ NAUT traded down $0.20 during mid-day trading on Thursday, hitting $2.51. 92,198 shares of the stock traded hands, compared to its average volume of 76,118. The company has a market cap of $314.40 million, a PE ratio of -4.56 and a beta of 1.20. Nautilus Biotechnology has a twelve month low of $2.19 and a twelve month high of $4.00. The firm has a 50 day simple moving average of $2.55 and a two-hundred day simple moving average of $2.68.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Guggenheim started coverage on Nautilus Biotechnology in a research report on Thursday, June 27th. They set a “buy” rating and a $6.00 price objective for the company. Jefferies Financial Group started coverage on shares of Nautilus Biotechnology in a research note on Monday, June 3rd. They issued a “hold” rating and a $3.00 price target on the stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.